Northwell Health’s Feinstein Institute for Medical Research announced a strategic alliance with GE Ventures to support the Feinstein’s Center for Bioelectronic Medicine (CBEM). With this investment, the Feinstein Institute will continue its work in discovering, developing and commercializing new diagnostic and therapeutic solutions in bioelectronic medicine for a wide range of acute and chronic diseases and injuries, including neurodegenerative diseases, cancer, diabetes and hypertension.
The Feinstein Institute is the worldwide leader for the advancement of scientific knowledge and intellectual property for bioelectronic medicine. Bioelectronic medicine represents the convergence of three well-established scientific fields: neuroscience, molecular and cell biology, and bioengineering. The Feinstein Institute team, led by Kevin J. Tracey, MD, a neurosurgeon who pioneered the field, has been working in this area since 1998, and Northwell Health has already invested $75 million in support of the underlying research. As bioelectronic solutions are successfully identified, tested and refined, CBEM will foster the creation of new companies to bring life-changing solutions to market.
The new alliance will greatly build upon groundbreaking work that started between the Feinstein Institute and a team of GE scientists specializing in bioelectronics research at GE’s Global Research Center in Niskayuna, NY. The alliance will be headquartered at the Feinstein Institute in Manhasset, NY, with continued close collaboration on research at GE’s Niskayuna research facility.
More information: Brückenkopf GmbH